Big charges hit CVS Health (NYSE: CVS) 2025 profit as revenue climbs
Rhea-AI Filing Summary
CVS Health reported strong 2025 top-line growth but sharply lower GAAP profit due to large one-time charges. Total revenues rose 7.8% to a record $402.1 billion, with fourth-quarter revenue up 8.2% to $105.7 billion.
Full-year GAAP diluted EPS fell to $1.39 from $3.66, mainly driven by a $5.7 billion goodwill impairment in the Health Services segment and about $1.2 billion of legacy litigation charges. By contrast, adjusted EPS increased to $6.75 from $5.42, reflecting stronger underlying operations, especially in Pharmacy & Consumer Wellness. Cash flow from operations was $10.6 billion. For 2026, CVS reaffirmed GAAP EPS guidance of $5.94–$6.14 and adjusted EPS of $7.00–$7.20, but lowered its operating cash flow outlook to at least $9.0 billion from at least $10.0 billion.
Positive
- Record 2025 revenue and higher adjusted EPS: Total revenue reached $402.1 billion, up 7.8%, while full-year adjusted EPS increased to $6.75 from $5.42, reflecting stronger underlying performance across segments.
- Strong Pharmacy & Consumer Wellness momentum: Segment revenue grew 11.9% to $139.4 billion and adjusted operating income rose 4.6% to $6.0 billion, driven by higher prescription volume and Rite Aid prescription file acquisitions.
- Solid overall cash generation: CVS produced $10.6 billion in cash flow from operations in 2025, giving the company meaningful financial resources despite sizeable non-recurring charges.
Negative
- Sharp decline in GAAP profitability from large charges: Operating income fell from $8.5 billion to $4.7 billion and GAAP diluted EPS dropped to $1.39 from $3.66, driven by a $5.7 billion goodwill impairment and about $1.2 billion of legacy litigation charges.
- Reduced 2026 cash flow guidance: Management cut its 2026 cash flow from operations outlook to at least $9.0 billion from at least $10.0 billion, signaling a weaker cash profile than previously expected.
- Health Care Benefits volatility: The segment posted a fourth-quarter adjusted operating loss of $676 million, and medical membership declined 504,000 year over year, reflecting pressure in individual exchange and Government product lines.
Insights
Revenue and adjusted earnings are solid, but heavy charges and lower cash guidance weaken the overall picture.
CVS Health delivered broad-based growth in 2025, with revenue up 7.8% to $402.1 billion and adjusted operating income rising 20.6% to $14.4 billion. Adjusted EPS climbed from $5.42 to $6.75, supported by stronger results in Health Care Benefits and Pharmacy & Consumer Wellness.
However, GAAP results deteriorated sharply. Operating income dropped from $8.5 billion to $4.7 billion, and GAAP diluted EPS fell to $1.39 from $3.66, primarily due to a $5.7 billion goodwill impairment in Health Care Delivery and about $1.2 billion of legacy litigation charges. These items are non-recurring but highlight past strategic and legal risks.
Operationally, Health Services adjusted operating income slipped 1.3% for the year, while Pharmacy & Consumer Wellness grew 4.6%, aided by Rite Aid prescription file acquisitions. The company generated $10.6 billion in operating cash flow but trimmed its 2026 guidance to at least $9.0 billion. Future disclosures around execution in Health Care Delivery and cash generation relative to the reaffirmed adjusted EPS range of $7.00–$7.20 will be important context for investors.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
How did CVS (CVS) perform financially in full-year 2025?
CVS Health grew 2025 revenue to $402.1 billion, up 7.8% year over year. GAAP diluted EPS fell to $1.39 from $3.66 due to large impairment and litigation charges, while adjusted EPS increased to $6.75, highlighting stronger underlying operations.
What were CVS (CVS) fourth-quarter 2025 earnings and revenue?
In Q4 2025, CVS Health reported revenue of $105.7 billion, up 8.2% from 2024. GAAP diluted EPS was $2.30, rising from $1.30, while adjusted EPS was $1.09, down from $1.19, mainly due to Medicare Part D seasonality impacts.
Why did CVS (CVS) GAAP earnings drop so much in 2025?
CVS GAAP earnings declined primarily because of a $5.7 billion goodwill impairment in its Health Care Delivery reporting unit and approximately $1.2 billion of legacy litigation charges. These non-recurring items significantly reduced operating income and GAAP EPS despite stronger adjusted performance.
What guidance did CVS (CVS) provide for 2026 earnings and cash flow?
For 2026, CVS reaffirmed GAAP diluted EPS guidance of $5.94–$6.14 and adjusted EPS of $7.00–$7.20. It updated its cash flow from operations outlook to at least $9.0 billion, lowering it from a prior target of at least $10.0 billion.
How did CVS (CVS) segments perform in 2025?
In 2025, Health Services revenue rose to $190.4 billion with slightly lower adjusted operating income. Pharmacy & Consumer Wellness revenue grew to $139.4 billion and adjusted operating income to $6.0 billion. Health Care Benefits revenue reached $143.4 billion, with adjusted operating income improving to $2.9 billion.
What were CVS (CVS) 2025 cash flow and balance sheet highlights?
CVS generated $10.6 billion in operating cash flow during 2025. Year-end 2025 total assets were $253.5 billion, total liabilities were $178.2 billion, and total CVS Health shareholders’ equity stood at $75.2 billion, reflecting a sizable capital base.
How is CVS (CVS) Health Care Benefits segment trending on medical costs?
The Health Care Benefits segment’s full-year medical benefit ratio improved to 91.2% from 92.5%, indicating relatively better medical cost performance. However, Q4 adjusted operating results showed a larger loss, and medical membership declined by 504,000 members versus year-end 2024.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
| Date of Report (Date of earliest event reported): | |||||
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
| (Address of principal executive offices) | (Zip Code) | |||||||
Registrant’s telephone number, including area code: | ||||||||
Former name or former address, if changed since last report: | N/A | |||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Section 2 - Financial Information
Item 2.02 Results of Operations and Financial Condition.
On February 10, 2026, CVS Health Corporation issued a press release announcing results for the three months and full year ended December 31, 2025. A copy of that press release is furnished herewith as Exhibit 99.1 and hereby incorporated in this Item 2.02 by reference.
The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (as amended, the “Exchange Act”) or otherwise subject to the liabilities of that Section, and shall not be or be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
Section 9 - Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The exhibits to this Current Report on Form 8-K are as follows:
INDEX TO EXHIBITS
| 99.1 | Press Release of CVS Health Corporation dated February 10, 2026 (furnished under Item 2.02). | |||||||
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CVS HEALTH CORPORATION | |||||||||||
| Date: | February 10, 2026 | By: | /s/ Brian O. Newman | ||||||||
| Brian O. Newman | |||||||||||
| Executive Vice President and Chief Financial Officer | |||||||||||
Exhibit 99.1
CVS HEALTH CORPORATION REPORTS FOURTH QUARTER AND FULL-YEAR 2025 RESULTS | |||||
Fourth Quarter Highlights | |||||
•Total revenues increased to $105.7 billion, up 8.2% compared to prior year •GAAP diluted EPS of $2.30 and Adjusted EPS of $1.09 | |||||
Full-Year Highlights | |||||
•Total revenues increased to a record high $402.1 billion, up 7.8% compared to prior year •GAAP diluted EPS of $1.39 and Adjusted EPS of $6.75 •Generated cash flow from operations of $10.6 billion | |||||
Operational Highlights | |||||
•CVS Pharmacy® successfully completed the transition to cost-based reimbursement across its Commercial, Third-Party Discount, Medicare and Medicaid businesses. •Aetna® continues to improve the experience for health care professionals and their patients, approving more than 95% of all eligible prior authorizations within 24 hours, with many completed instantaneously. •Caremark® closes out 2025 with significant customer wins and strong retention, providing momentum into 2026. | |||||
2026 Full-Year Guidance | |||||
•Confirmed GAAP diluted EPS guidance range of $5.94 to $6.14 •Confirmed Adjusted EPS guidance range of $7.00 to $7.20 •Updated cash flow from operations guidance to at least $9.0 billion from at least $10.0 billion | |||||
CEO Commentary | |||||
“Our fourth quarter and full-year results demonstrate the progress we are making in transforming the health care experience with our unique collection of businesses. From lowering drug prices, to improving navigation of health care, to being the front door of care across our country, we are well positioned to achieve our ambition to be the most trusted health care company in America.” - David Joyner, CVS Health President and CEO | |||||
WOONSOCKET, RHODE ISLAND, February 10, 2026 - CVS Health Corporation (NYSE: CVS) today announced operating results for the three months and year ended December 31, 2025. | |||||
Financial Results Summary | |||||
| Three Months Ended December 31, | |||||||||||||||||
| In millions, except per share amounts | 2025 | 2024 | Change | ||||||||||||||
Total revenues | $ | 105,693 | $ | 97,710 | $ | 7,983 | |||||||||||
| Operating income | 2,112 | 2,368 | (256) | ||||||||||||||
Adjusted operating income (1) | 2,597 | 2,728 | (131) | ||||||||||||||
| Diluted earnings per share | $ | 2.30 | $ | 1.30 | $ | 1.00 | |||||||||||
Adjusted EPS (2) | $ | 1.09 | $ | 1.19 | $ | (0.10) | |||||||||||
Fourth quarter GAAP diluted EPS of $2.30 increased from $1.30 in the prior year. Adjusted EPS of $1.09 decreased from $1.19 in the prior year, primarily due to a decline in adjusted operating income in the Health Care Benefits segment, reflecting changes in the seasonality of the Medicare Part D program due to the impact of the Inflation Reduction Act (“IRA”).
1
Consolidated fourth quarter and full-year results
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||
| In millions, except per share amounts | 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||||
Total revenues | $ | 105,693 | $ | 97,710 | $ | 7,983 | $ | 402,067 | $ | 372,809 | $ | 29,258 | |||||||||||||||||||||||
| Operating income | 2,112 | 2,368 | (256) | 4,660 | 8,516 | (3,856) | |||||||||||||||||||||||||||||
Adjusted operating income (1) | 2,597 | 2,728 | (131) | 14,443 | 11,976 | 2,467 | |||||||||||||||||||||||||||||
| Net income | 2,923 | 1,623 | 1,300 | 1,728 | 4,586 | (2,858) | |||||||||||||||||||||||||||||
| Diluted earnings per share | $ | 2.30 | $ | 1.30 | $ | 1.00 | $ | 1.39 | $ | 3.66 | $ | (2.27) | |||||||||||||||||||||||
Adjusted EPS (2) | $ | 1.09 | $ | 1.19 | $ | (0.10) | $ | 6.75 | $ | 5.42 | $ | 1.33 | |||||||||||||||||||||||
For the three months and year ended December 31, 2025 compared to the prior year:
•Total revenues increased 8.2% in the three months ended December 31, 2025 and increased 7.8% in the year ended December 31, 2025 driven by growth across all operating segments.
•Operating income decreased 10.8% in the three months ended December 31, 2025 primarily due to a decrease in adjusted operating income and a decline in net realized capital gains compared to the prior year.
•Operating income decreased 45.3% for the year ended December 31, 2025 primarily due to a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit and approximately $1.2 billion of legacy litigation charges, both recorded during the year ended December 31, 2025. These decreases were partially offset by an increase in adjusted operating income and the absence of approximately $1.2 billion of restructuring charges recorded in the prior year.
•Adjusted operating income decreased 4.8% in the three months ended December 31, 2025 and increased 20.6% in the year ended December 31, 2025. See pages 3 through 5 for a discussion of the adjusted operating income performance of the Company’s segments.
•Interest expense increased $29 million, or 3.8%, and $161 million, or 5.4%, respectively, primarily as a result of long-term debt issuances in December 2024 and August 2025.
•The Company recorded an income tax benefit at an effective income tax rate of (115.9)% in the fourth quarter of 2025, compared to income tax expense at an effective income tax rate of 23.7% in the prior year. The change was due to a worthless stock deduction associated with a subsidiary that filed for bankruptcy in 2025.
•The effective income tax rate for the full year decreased to 19.1% compared to 25.4% in the prior year due to the worthless stock deduction described above, partially offset by the impact of the goodwill impairment charge and the legacy litigation charges recorded during 2025, both of which were not deductible for income tax purposes.
2
Health Care Benefits segment
The Health Care Benefits segment offers a full range of insured and self-insured (“ASC”) medical, pharmacy, dental and behavioral health products and services. The segment results for the three months and years ended December 31, 2025 and 2024 were as follows:
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||
| In millions, except percentages | 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||||
| Total revenues | $ | 36,293 | $ | 32,958 | $ | 3,335 | $ | 143,354 | $ | 130,665 | $ | 12,689 | |||||||||||||||||||||||
Adjusted operating income (loss) (1) | (676) | (439) | (237) | 2,939 | 307 | 2,632 | |||||||||||||||||||||||||||||
Medical benefit ratio (“MBR”) (3) | 94.8 | % | 94.8 | % | — | % | 91.2 | % | 92.5 | % | (1.3) | % | |||||||||||||||||||||||
Medical membership (4) | 26.6 | 27.1 | (0.5) | ||||||||||||||||||||||||||||||||
•Total revenues increased 10.1% and 9.7% for the three months and year ended December 31, 2025, respectively, compared to the prior year primarily driven by increases in the Government business, largely due to the impact of the IRA on the Medicare Part D program.
•Adjusted operating loss increased $237 million for the three months ended December 31, 2025 compared to the prior year primarily driven by changes in the seasonality of the Medicare Part D program due to the impact of the IRA and the unfavorable year-over-year impact of premium deficiency reserves, partially offset by improved underlying performance in the Government business.
•Adjusted operating income increased $2.6 billion for the year ended December 31, 2025 compared to the prior year primarily driven by improved underlying performance in the Government business and higher favorable prior year development.
•The MBR of 94.8% in the three months ended December 31, 2025 remained consistent with the prior year as improved underlying performance in the Government business was offset by changes in the seasonality of the Medicare Part D program due to the impact of the IRA.
•The MBR decreased to 91.2% in the year ended December 31, 2025 compared to 92.5% in the prior year primarily driven by improved underlying performance in the Government business and higher favorable prior year development.
•Medical membership as of December 31, 2025 of 26.6 million decreased 112,000 members compared with September 30, 2025 reflecting declines in the individual exchange product line, partially offset by an increase in Commercial ASC membership. Medical membership as of December 31, 2025 decreased 504,000 members compared with December 31, 2024, reflecting declines in the individual exchange and Government product lines, partially offset by an increase in Commercial ASC membership.
•Prior years’ health care costs payable estimates developed favorably by $2.0 billion during the year ended December 31, 2025. This development is reported on a basis consistent with the prior years’ development reported in the health care costs payable table in the Company’s annual audited financial statements and does not directly correspond to an increase in 2025 operating results.
•Days claims payable were 38.9 days as of December 31, 2025, a decrease of 3.6 days compared to September 30, 2025.
See the supplemental information on page 18 for additional information regarding the performance of the Health Care Benefits segment.
3
Health Services segment
The Health Services segment provides a full range of pharmacy benefit management (“PBM”) solutions, delivers health care services in its medical clinics, virtually, and in the home, and offers provider enablement solutions. The segment results for the three months and years ended December 31, 2025 and 2024 were as follows:
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||
| In millions | 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||||
| Total revenues | $ | 51,244 | $ | 47,020 | $ | 4,224 | $ | 190,425 | $ | 173,605 | $ | 16,820 | |||||||||||||||||||||||
Adjusted operating income (1) | 1,923 | 1,761 | 162 | 7,151 | 7,243 | (92) | |||||||||||||||||||||||||||||
Pharmacy claims processed (5) (6) | 491.9 | 499.4 | (7.5) | 1,900.7 | 1,917.6 | (16.9) | |||||||||||||||||||||||||||||
•Total revenues increased 9.0% and 9.7% for the three months and year ended December 31, 2025, respectively, compared to the prior year primarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements.
•Adjusted operating income increased 9.2% for the three months ended December 31, 2025 compared to the prior year primarily driven by improved purchasing economics, partially offset by continued pharmacy client price improvements.
•Adjusted operating income decreased 1.3% for the year ended December 31, 2025 compared to the prior year primarily driven by continued pharmacy client price improvements and the impact of a higher medical benefit ratio in the Company’s health care delivery business, partially offset by improved purchasing economics and pharmacy drug mix.
•Pharmacy claims processed decreased 1.5% and 0.9% on a 30-day equivalent basis for the three months and year ended December 31, 2025, respectively, compared to the prior year.
See the supplemental information on page 19 for additional information regarding the performance of the Health Services segment.
4
Pharmacy & Consumer Wellness segment
The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations, provides ancillary pharmacy services including pharmacy patient care programs, diagnostic testing and vaccination administration, and sells a wide assortment of health and wellness products and general merchandise. The segment also provides pharmacy fulfillment services to support the Health Services segment’s specialty and mail order pharmacy offerings. The segment results for the three months and years ended December 31, 2025 and 2024 were as follows:
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||||||||||||||
| In millions | 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||||||||||||
| Total revenues | $ | 37,660 | $ | 33,514 | $ | 4,146 | $ | 139,367 | $ | 124,500 | $ | 14,867 | |||||||||||||||||||||||
Adjusted operating income (1) | 1,911 | 1,758 | 153 | 6,040 | 5,774 | 266 | |||||||||||||||||||||||||||||
Prescriptions filled (5) (6) | 473.8 | 445.9 | 27.9 | 1,808.8 | 1,715.5 | 93.3 | |||||||||||||||||||||||||||||
•Total revenues increased 12.4% and 11.9% for the three months and year ended December 31, 2025, respectively, compared to the prior year primarily driven by pharmacy drug mix and increased prescription volume, including incremental volume resulting from the Company’s Rite Aid prescription file acquisitions, partially offset by continued pharmacy reimbursement pressure and the impact of recent generic drug introductions.
•Adjusted operating income increased 8.7% and 4.6% for the three months and year ended December 31, 2025, respectively, compared to the prior year primarily driven by increased prescription volume, including incremental volume resulting from the Company’s Rite Aid prescription file acquisitions, as well as favorable drug mix, partially offset by continued pharmacy reimbursement pressure and increased investments in the segment’s colleagues and capabilities.
•Prescriptions filled increased 6.3% and 5.4% on a 30-day equivalent basis for the three months and year ended December 31, 2025, respectively, compared to the prior year primarily driven by increased utilization and incremental volume resulting from the Company’s Rite Aid prescription file acquisitions.
•Same store prescription volume(6)(11) increased 9.7% and 8.0% on a 30-day equivalent basis for the three months and year ended December 31, 2025, respectively, compared to the prior year.
See the supplemental information on page 20 for additional information regarding the performance of the Pharmacy & Consumer Wellness segment.
5
Teleconference and webcast
The Company will be holding a conference call today for investors at 8:00 a.m. (Eastern Time) to discuss its fourth quarter and full-year results. An audio webcast of the call will be broadcast simultaneously for all interested parties through the Investor Relations section of the CVS Health website at http://investors.cvshealth.com. This webcast will be archived and available on the website for a one-year period following the conference call.
Non-GAAP Financial Information
The Company presents both GAAP and non-GAAP financial measures in this press release to assist in the comparison of the Company’s past financial performance with its current financial performance. See “Non-GAAP Financial Information” beginning on page 11 and endnotes beginning on page 24 for explanations of non-GAAP financial measures presented in this press release. See pages 14 through 16 and page 23 for reconciliations of each non-GAAP financial measure used in this release to the most directly comparable GAAP financial measure.
About CVS Health
CVS Health is a leading health solutions company building a world of health around every consumer, wherever they are. As of December 31, 2025, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 87 million plan members. The Company also serves an estimated more than 37 million people through traditional, voluntary and consumer-directed health insurance products and related services, including highly rated Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.
Cautionary statement concerning forward-looking statements
The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, the information under the headings “2026 Full-Year Guidance”, “CEO Commentary” and “Financial Results Summary” and the information included in the reconciliations and endnotes. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in our Securities and Exchange Commission (“SEC”) filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025 and our Current Reports on Form 8-K.
You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health’s forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events, uncertainties or otherwise.
Investor Contact: Larry McGrath | Executive Vice President, Capital Markets | (800) 201-0938
Media Contact: Ethan Slavin | Executive Director, Corporate Communications | (860) 273-6095
- Tables Follow -
6
CVS HEALTH CORPORATION
Condensed Consolidated Statements of Operations
(Unaudited)
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||||
| In millions, except per share amounts | 2025 | 2024 | 2025 | 2024 | |||||||||||||||||||
| Revenues: | |||||||||||||||||||||||
| Products | $ | 67,042 | $ | 61,911 | $ | 249,908 | $ | 231,521 | |||||||||||||||
| Premiums | 34,017 | 30,913 | 134,751 | 122,896 | |||||||||||||||||||
| Services | 4,040 | 4,131 | 15,175 | 16,239 | |||||||||||||||||||
| Net investment income | 594 | 755 | 2,233 | 2,153 | |||||||||||||||||||
| Total revenues | 105,693 | 97,710 | 402,067 | 372,809 | |||||||||||||||||||
| Operating costs: | |||||||||||||||||||||||
| Cost of products sold | 59,060 | 55,268 | 221,167 | 206,287 | |||||||||||||||||||
| Health care costs | 33,066 | 29,543 | 125,538 | 115,121 | |||||||||||||||||||
| Operating expenses | 11,455 | 10,521 | 44,977 | 41,706 | |||||||||||||||||||
| Goodwill impairment | — | — | 5,725 | — | |||||||||||||||||||
| Restructuring charges | — | 10 | — | 1,179 | |||||||||||||||||||
| Total operating costs | 103,581 | 95,342 | 397,407 | 364,293 | |||||||||||||||||||
| Operating income | 2,112 | 2,368 | 4,660 | 8,516 | |||||||||||||||||||
Interest expense | (787) | (758) | (3,119) | (2,958) | |||||||||||||||||||
Gain on early extinguishment of debt | — | 491 | — | 491 | |||||||||||||||||||
Gain on deconsolidation of subsidiary | — | — | 483 | — | |||||||||||||||||||
| Other income | 29 | 25 | 112 | 99 | |||||||||||||||||||
| Income before income tax provision | 1,354 | 2,126 | 2,136 | 6,148 | |||||||||||||||||||
| Income tax provision (benefit) | (1,569) | 503 | 408 | 1,562 | |||||||||||||||||||
| Net income | 2,923 | 1,623 | 1,728 | 4,586 | |||||||||||||||||||
| Net loss attributable to noncontrolling interests | 20 | 21 | 40 | 28 | |||||||||||||||||||
| Net income attributable to CVS Health | $ | 2,943 | $ | 1,644 | $ | 1,768 | $ | 4,614 | |||||||||||||||
| Net income per share attributable to CVS Health: | |||||||||||||||||||||||
| Basic | $ | 2.32 | $ | 1.31 | $ | 1.40 | $ | 3.67 | |||||||||||||||
| Diluted | $ | 2.30 | $ | 1.30 | $ | 1.39 | $ | 3.66 | |||||||||||||||
| Weighted average shares outstanding: | |||||||||||||||||||||||
| Basic | 1,270 | 1,259 | 1,267 | 1,259 | |||||||||||||||||||
| Diluted | 1,277 | 1,261 | 1,271 | 1,262 | |||||||||||||||||||
7
CVS HEALTH CORPORATION
Condensed Consolidated Balance Sheets
(Unaudited)
| At December 31, | |||||||||||
| In millions | 2025 | 2024 | |||||||||
| Assets: | |||||||||||
| Cash and cash equivalents | $ | 8,453 | $ | 8,586 | |||||||
| Investments | 2,145 | 2,407 | |||||||||
| Accounts receivable, net | 39,779 | 36,469 | |||||||||
| Inventories | 19,246 | 18,107 | |||||||||
| Other current assets | 5,091 | 3,076 | |||||||||
| Total current assets | 74,714 | 68,645 | |||||||||
| Long-term investments | 32,669 | 28,934 | |||||||||
| Property and equipment, net | 13,083 | 12,993 | |||||||||
| Operating lease right-of-use assets | 14,973 | 15,944 | |||||||||
| Goodwill | 85,478 | 91,272 | |||||||||
| Intangible assets, net | 25,508 | 27,323 | |||||||||
| Separate accounts assets | 1,994 | 3,311 | |||||||||
| Other assets | 5,119 | 4,793 | |||||||||
| Total assets | $ | 253,538 | $ | 253,215 | |||||||
| Liabilities: | |||||||||||
| Accounts payable | $ | 17,641 | $ | 15,892 | |||||||
| Pharmacy claims and discounts payable | 26,344 | 24,166 | |||||||||
| Health care costs payable | 15,399 | 15,064 | |||||||||
Accrued expenses and other current liabilities | 22,387 | 20,810 | |||||||||
| Other insurance liabilities | 1,116 | 1,183 | |||||||||
| Current portion of operating lease liabilities | 1,737 | 1,751 | |||||||||
| Short-term debt | — | 2,119 | |||||||||
| Current portion of long-term debt | 4,068 | 3,624 | |||||||||
| Total current liabilities | 88,692 | 84,609 | |||||||||
| Long-term operating lease liabilities | 13,643 | 14,899 | |||||||||
| Long-term debt | 60,502 | 60,527 | |||||||||
| Deferred income taxes | 3,832 | 3,806 | |||||||||
| Separate accounts liabilities | 1,994 | 3,311 | |||||||||
| Other long-term insurance liabilities | 4,716 | 4,902 | |||||||||
| Other long-term liabilities | 4,777 | 5,431 | |||||||||
| Total liabilities | 178,156 | 177,485 | |||||||||
| Shareholders’ equity: | |||||||||||
| Preferred stock | — | — | |||||||||
| Common stock and capital surplus | 50,402 | 49,661 | |||||||||
| Treasury stock | (36,790) | (36,818) | |||||||||
| Retained earnings | 61,196 | 62,837 | |||||||||
| Accumulated other comprehensive income (loss) | 406 | (120) | |||||||||
| Total CVS Health shareholders’ equity | 75,214 | 75,560 | |||||||||
| Noncontrolling interests | 168 | 170 | |||||||||
| Total shareholders’ equity | 75,382 | 75,730 | |||||||||
| Total liabilities and shareholders’ equity | $ | 253,538 | $ | 253,215 | |||||||
8
CVS HEALTH CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Year Ended December 31, | |||||||||||
| In millions | 2025 | 2024 | |||||||||
| Cash flows from operating activities: | |||||||||||
| Cash receipts from customers | $ | 389,128 | $ | 357,995 | |||||||
| Cash paid for inventory, prescriptions dispensed and health services rendered | (216,493) | (197,726) | |||||||||
| Insurance benefits paid | (121,238) | (109,464) | |||||||||
| Cash paid to other suppliers and employees | (37,570) | (38,821) | |||||||||
| Interest and investment income received | 1,969 | 1,735 | |||||||||
| Interest paid | (2,991) | (2,909) | |||||||||
| Income taxes paid | (2,166) | (1,703) | |||||||||
| Net cash provided by operating activities | 10,639 | 9,107 | |||||||||
| Cash flows from investing activities: | |||||||||||
| Proceeds from sales and maturities of investments | 12,383 | 10,353 | |||||||||
| Purchases of investments | (15,012) | (15,191) | |||||||||
| Purchases of property and equipment | (2,832) | (2,781) | |||||||||
| Acquisitions (net of cash and restricted cash acquired) | (436) | (95) | |||||||||
| Other | 26 | 101 | |||||||||
| Net cash used in investing activities | (5,871) | (7,613) | |||||||||
| Cash flows from financing activities: | |||||||||||
| Commercial paper borrowings (repayments), net | (2,119) | 1,919 | |||||||||
| Proceeds from issuance of long-term debt | 3,969 | 7,913 | |||||||||
| Repayments of long-term debt | (3,629) | (4,773) | |||||||||
| Repurchase of common stock | — | (3,023) | |||||||||
| Dividends paid | (3,397) | (3,373) | |||||||||
| Proceeds from exercise of stock options | 394 | 361 | |||||||||
| Payments for taxes related to net share settlement of equity awards | (158) | (185) | |||||||||
| Other | — | 26 | |||||||||
| Net cash used in financing activities | (4,940) | (1,135) | |||||||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | (172) | 359 | |||||||||
| Cash, cash equivalents and restricted cash at the beginning of the period | 8,884 | 8,525 | |||||||||
| Cash, cash equivalents and restricted cash at the end of the period | $ | 8,712 | $ | 8,884 | |||||||
9
CVS HEALTH CORPORATION
Condensed Consolidated Statements of Cash Flows
(Unaudited)
| Year Ended December 31, | |||||||||||
| In millions | 2025 | 2024 | |||||||||
| Reconciliation of net income to net cash provided by operating activities: | |||||||||||
| Net income | $ | 1,728 | $ | 4,586 | |||||||
| Adjustments required to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 4,606 | 4,597 | |||||||||
| Goodwill impairment | 5,725 | — | |||||||||
| Stock-based compensation | 535 | 540 | |||||||||
Loss on sale of subsidiary | 236 | — | |||||||||
Gain on early extinguishment of debt | — | (491) | |||||||||
Gain on deconsolidation of subsidiary | (483) | — | |||||||||
| Restructuring charges (impairment of long-lived assets) | — | 840 | |||||||||
| Deferred income taxes | 102 | (572) | |||||||||
Other items | (336) | (502) | |||||||||
| Change in operating assets and liabilities, net of effects from acquisitions: | |||||||||||
| Accounts receivable, net | (3,498) | (1,301) | |||||||||
| Inventories | (1,267) | (102) | |||||||||
| Other assets | (2,593) | (38) | |||||||||
| Accounts payable and pharmacy claims and discounts payable | 3,855 | 2,335 | |||||||||
| Health care costs payable and other insurance liabilities | 16 | 2,757 | |||||||||
| Other liabilities | 2,013 | (3,542) | |||||||||
| Net cash provided by operating activities | $ | 10,639 | $ | 9,107 | |||||||
10
Non-GAAP Financial Information
The Company uses non-GAAP financial measures to analyze underlying business performance and trends. The Company believes that providing these non-GAAP financial measures enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current and expected future performance. These non-GAAP financial measures, which are included in this press release and which may be referred to on the conference call discussing the Company’s fourth quarter and full-year 2025 financial results, are provided as supplemental information to the financial measures presented in this press release and discussed on the conference call that are calculated and presented in accordance with GAAP. Non-GAAP financial measures should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. The Company’s definitions of its non-GAAP financial measures may not be comparable to similarly titled measures reported by other companies.
Non-GAAP financial measures such as consolidated adjusted operating income, adjusted earnings per share (“EPS”) and adjusted income attributable to CVS Health exclude from the relevant GAAP metrics, as applicable: amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance.
For the periods covered in this press release, the following items are excluded from the non-GAAP financial measures described above, as applicable, because the Company believes they neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance:
•The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised.
•The Company’s net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in net investment income (loss) within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company’s business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends.
•During the three months and year ended December 31, 2025 and 2024, the acquisition-related integration costs relate to the acquisitions of Signify Health, Inc. and Oak Street Health, Inc. The acquisition-related integration costs are reflected in operating expenses within the Corporate/Other segment.
11
•During the year ended December 31, 2025, the goodwill impairment charge relates to the Health Care Delivery reporting unit within the Health Services segment.
•During the year ended December 31, 2025, the Health Care Delivery clinic closure charge primarily relates to the write down of long-lived assets in connection with the planned closure of certain existing Oak Street Health clinics in 2026, as well as associated severance and employee-related costs expected to be incurred. The Health Care Delivery clinic closure charge is reflected in operating expenses within the Health Services segment.
•During the years ended December 31, 2025 and 2024, the opioid litigation charges relate to changes in the Company’s accrual related to ongoing opioid litigation matters.
•During the year ended December 31, 2025 and the three months and year ended December 31, 2024, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the Company’s evaluation of corporate office real estate space in response to its ongoing flexible work arrangement. The office real estate optimization charges are reflected in operating expenses within each segment.
•During the year ended December 31, 2025, the Company recorded legacy litigation charges related to two court decisions associated with its past business practices.
In April 2025, a jury found Omnicare, LLC (“Omnicare”) and CVS Health Corporation liable in connection with alleged violations of the federal False Claims Act related to dispensing practices by Omnicare from 2010, prior to its acquisition by the Company in 2015, through 2018. Damages were found only with respect to Omnicare. Accordingly, the Company recorded a litigation charge of $387 million during the first quarter of 2025. During the second quarter of 2025, the Company recorded a charge of $542 million, reflecting penalties assessed under the False Claims Act. These litigation charges are reflected in operating expenses within the Pharmacy & Consumer Wellness segment.
In June 2025, a court found certain subsidiaries of CVS Health Corporation liable for damages in connection with a complaint filed in February 2014, in which the government declined to intervene, related to PBM direct and indirect remuneration reporting practices for two clients from 2010 through 2016, which the Company has since modified. In connection with this court decision, the Company recorded a litigation charge of $291 million during the second quarter of 2025. This litigation charge is reflected in operating expenses within the Health Services segment.
•During the year ended December 31, 2025, the loss on the wind down and sale of Accountable Care assets represents the pre-tax loss on the divestiture of the Company’s Medicare Shared Savings Program (“MSSP”) operations, which the Company sold in March 2025, as well as costs incurred in connection with the process of winding down the Company’s Accountable Care Organization Realizing Equity, Access and Community Health (“ACO REACH”) operations. The loss on Accountable Care assets is reflected in operating expenses within the Health Services segment.
•During the three months ended December 31, 2024, the restructuring charges are primarily comprised of a stock-based compensation charge. During the year ended December 31, 2024, the restructuring charges also include a store impairment charge, corporate workforce optimization costs, including severance and employee-related costs, and other asset impairment and related charges associated with the discontinuation of certain non-core assets. During the third quarter of 2024, the Company finalized an enterprise-wide restructuring plan intended to streamline and simplify the organization, improve efficiency and reduce costs. In connection with this restructuring plan, the Company completed a strategic review of its retail business and determined that it planned to close additional retail stores in 2025, and, accordingly, it recorded a store impairment charge to write down the associated lease right-of-use assets and property and equipment. In addition, during the third quarter of 2024, the Company also conducted a review of its various strategic assets and determined that it would discontinue the use of certain non-core assets, at which time impairment losses were recorded to write down the carrying value of these assets to the Company’s best estimate of their fair value. The restructuring charges associated with the store impairments are reflected within the Pharmacy & Consumer Wellness segment, other asset impairments and related charges are reflected within the Corporate/Other and Pharmacy & Consumer Wellness segments and corporate workforce optimization costs, including severance and employee-related costs, as well as the stock-based compensation charge, are reflected within the Corporate/Other segment.
12
•During the three months and year ended December 31, 2024, the gain on early extinguishment of debt relates to the Company’s repayment of approximately $2.6 billion of its outstanding senior notes in December 2024, pursuant to its tender offer for such senior notes.
•During the year ended December 31, 2025, the gain on deconsolidation of subsidiary relates to Omnicare, a wholly-owned indirect subsidiary of CVS Health Corporation, and certain of its subsidiary entities (collectively, the “Omnicare Entities”). In September 2025, the Omnicare Entities voluntarily initiated Chapter 11 proceedings under the U.S. Bankruptcy Code, at which time the Company determined that it no longer retained control of the Omnicare Entities and deconsolidated the subsidiaries.
•Following the voluntarily initiation of Chapter 11 proceedings described above, it was determined that the Company’s investment in a subsidiary became worthless in 2025. Consequently, the Company recognized a related net tax benefit of approximately $1.9 billion in the aggregate during the three months and year ended December 31, 2025.
•The corresponding tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health and Adjusted EPS above. The nature of each non-GAAP adjustment is evaluated to determine whether a discrete adjustment should be made to the adjusted income tax provision.
See endnotes (1) and (2) on page 24 for definitions of non-GAAP financial measures. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure are presented on pages 14 through 16 and page 23.
13
Reconciliations of Non-GAAP Financial Measures to the Most Directly Comparable GAAP Financial Measures
Adjusted Operating Income
(Unaudited)
The following are reconciliations of consolidated operating income (GAAP measure) to consolidated adjusted operating income, as well as reconciliations of segment GAAP operating income (loss) to segment adjusted operating income (loss):
| Three Months Ended December 31, 2025 | |||||||||||||||||||||||||||||
| In millions | Health Care Benefits | Health Services | Pharmacy & Consumer Wellness | Corporate/ Other | Consolidated Totals | ||||||||||||||||||||||||
| Operating income (loss) (GAAP measure) | $ | (936) | $ | 1,790 | $ | 1,846 | $ | (588) | $ | 2,112 | |||||||||||||||||||
| Amortization of intangible assets | 274 | 143 | 65 | 1 | 483 | ||||||||||||||||||||||||
| Net realized capital (gains) losses | (14) | (10) | — | 9 | (15) | ||||||||||||||||||||||||
| Acquisition-related integration costs | — | — | — | 17 | 17 | ||||||||||||||||||||||||
Adjusted operating income (loss) (1) | $ | (676) | $ | 1,923 | $ | 1,911 | $ | (561) | $ | 2,597 | |||||||||||||||||||
| Three Months Ended December 31, 2024 | ||||||||||||||||||||||||||||||||
| In millions | Health Care Benefits | Health Services | Pharmacy & Consumer Wellness | Corporate/ Other | Consolidated Totals | |||||||||||||||||||||||||||
| Operating income (loss) (GAAP measure) | $ | (757) | $ | 1,903 | $ | 1,694 | $ | (472) | $ | 2,368 | ||||||||||||||||||||||
| Amortization of intangible assets | 294 | 147 | 61 | 1 | 503 | |||||||||||||||||||||||||||
| Net realized capital (gains) losses | 15 | (289) | — | 68 | (206) | |||||||||||||||||||||||||||
| Acquisition-related integration costs | — | — | — | 40 | 40 | |||||||||||||||||||||||||||
| Office real estate optimization charges | 9 | — | 3 | 1 | 13 | |||||||||||||||||||||||||||
| Restructuring charges | — | — | — | 10 | 10 | |||||||||||||||||||||||||||
Adjusted operating income (loss) (1) | $ | (439) | $ | 1,761 | $ | 1,758 | $ | (352) | $ | 2,728 | ||||||||||||||||||||||
14
| Year Ended December 31, 2025 | |||||||||||||||||||||||||||||
| In millions | Health Care Benefits | Health Services | Pharmacy & Consumer Wellness | Corporate/ Other | Consolidated Totals | ||||||||||||||||||||||||
| Operating income (loss) (GAAP measure) | $ | 1,793 | $ | 220 | $ | 4,860 | $ | (2,213) | $ | 4,660 | |||||||||||||||||||
| Amortization of intangible assets | 1,155 | 569 | 249 | 3 | 1,976 | ||||||||||||||||||||||||
| Net realized capital (gains) losses | (13) | (25) | — | 82 | 44 | ||||||||||||||||||||||||
| Acquisition-related integration costs | — | — | — | 117 | 117 | ||||||||||||||||||||||||
| Goodwill impairment | — | 5,725 | — | — | 5,725 | ||||||||||||||||||||||||
| Health Care Delivery clinic closure charge | — | 83 | — | — | 83 | ||||||||||||||||||||||||
| Opioid litigation charge | — | — | — | 320 | 320 | ||||||||||||||||||||||||
| Office real estate optimization charges | 4 | — | 2 | 4 | 10 | ||||||||||||||||||||||||
| Legacy litigation charges | — | 291 | 929 | — | 1,220 | ||||||||||||||||||||||||
| Loss on Accountable Care assets | — | 288 | — | — | 288 | ||||||||||||||||||||||||
Adjusted operating income (loss) (1) | $ | 2,939 | $ | 7,151 | $ | 6,040 | $ | (1,687) | $ | 14,443 | |||||||||||||||||||
| Year Ended December 31, 2024 | |||||||||||||||||||||||||||||
| In millions | Health Care Benefits | Health Services | Pharmacy & Consumer Wellness | Corporate/ Other | Consolidated Totals | ||||||||||||||||||||||||
| Operating income (loss) (GAAP measure) | $ | (984) | $ | 6,937 | $ | 4,770 | $ | (2,207) | $ | 8,516 | |||||||||||||||||||
| Amortization of intangible assets | 1,175 | 595 | 253 | 2 | 2,025 | ||||||||||||||||||||||||
Net realized capital (gains) losses | 97 | (289) | — | 75 | (117) | ||||||||||||||||||||||||
| Acquisition-related integration costs | — | — | — | 243 | 243 | ||||||||||||||||||||||||
| Opioid litigation charge | — | — | — | 100 | 100 | ||||||||||||||||||||||||
| Office real estate optimization charges | 19 | — | 4 | 7 | 30 | ||||||||||||||||||||||||
| Restructuring charges | — | — | 747 | 432 | 1,179 | ||||||||||||||||||||||||
Adjusted operating income (loss) (1) | $ | 307 | $ | 7,243 | $ | 5,774 | $ | (1,348) | $ | 11,976 | |||||||||||||||||||
15
Adjusted Earnings Per Share
(Unaudited)
The following are reconciliations of net income attributable to CVS Health to adjusted income attributable to CVS Health and calculations of GAAP diluted earnings per share and Adjusted EPS:
| Three Months Ended December 31, 2025 | Three Months Ended December 31, 2024 | ||||||||||||||||||||||
| In millions, except per share amounts | Total Company | Per Common Share | Total Company | Per Common Share | |||||||||||||||||||
| Net income attributable to CVS Health (GAAP measure) | $ | 2,943 | $ | 2.30 | $ | 1,644 | $ | 1.30 | |||||||||||||||
| Amortization of intangible assets | 483 | 0.38 | 503 | 0.40 | |||||||||||||||||||
| Net realized capital gains | (15) | (0.01) | (206) | (0.16) | |||||||||||||||||||
| Acquisition-related integration costs | 17 | 0.01 | 40 | 0.03 | |||||||||||||||||||
| Office real estate optimization charges | — | — | 13 | 0.01 | |||||||||||||||||||
| Restructuring charges | — | — | 10 | 0.01 | |||||||||||||||||||
| Gain on early extinguishment of debt | — | — | (491) | (0.39) | |||||||||||||||||||
| Tax benefit from worthless stock deduction | (1,928) | (1.51) | — | — | |||||||||||||||||||
| Tax impact of other non-GAAP adjustments | (113) | (0.08) | (7) | (0.01) | |||||||||||||||||||
Adjusted income attributable to CVS Health (2) | $ | 1,387 | $ | 1.09 | $ | 1,506 | $ | 1.19 | |||||||||||||||
| Weighted average diluted shares outstanding | 1,277 | 1,261 | |||||||||||||||||||||
| Year Ended December 31, 2025 | Year Ended December 31, 2024 | ||||||||||||||||||||||
| In millions, except per share amounts | Total Company | Per Common Share | Total Company | Per Common Share | |||||||||||||||||||
| Net income attributable to CVS Health (GAAP measure) | $ | 1,768 | $ | 1.39 | $ | 4,614 | $ | 3.66 | |||||||||||||||
| Amortization of intangible assets | 1,976 | 1.56 | 2,025 | 1.61 | |||||||||||||||||||
| Net realized capital (gains) losses | 44 | 0.03 | (117) | (0.09) | |||||||||||||||||||
| Acquisition-related integration costs | 117 | 0.09 | 243 | 0.19 | |||||||||||||||||||
| Goodwill impairment | 5,725 | 4.50 | — | — | |||||||||||||||||||
| Health Care Delivery clinic closure charge | 83 | 0.07 | — | — | |||||||||||||||||||
| Opioid litigation charges | 320 | 0.25 | 100 | 0.08 | |||||||||||||||||||
| Office real estate optimization charges | 10 | 0.01 | 30 | 0.02 | |||||||||||||||||||
| Legacy litigation charges | 1,220 | 0.96 | — | — | |||||||||||||||||||
| Loss on Accountable Care assets | 288 | 0.23 | — | — | |||||||||||||||||||
| Restructuring charges | — | — | 1,179 | 0.93 | |||||||||||||||||||
| Gain on early extinguishment of debt | — | — | (491) | (0.39) | |||||||||||||||||||
| Gain on deconsolidation of subsidiary | (483) | (0.38) | — | — | |||||||||||||||||||
| Tax benefit from worthless stock deduction | (1,928) | (1.51) | — | — | |||||||||||||||||||
| Tax impact of other non-GAAP adjustments | (568) | (0.45) | (745) | (0.59) | |||||||||||||||||||
Adjusted income attributable to CVS Health (2) | $ | 8,572 | $ | 6.75 | $ | 6,838 | $ | 5.42 | |||||||||||||||
| Weighted average diluted shares outstanding | 1,271 | 1,262 | |||||||||||||||||||||
16
Supplemental Information
(Unaudited)
The Company’s segments maintain separate financial information, and the Company’s chief operating decision maker (the “CODM”) evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income. Adjusted operating income is defined as operating income (loss) (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance as further described in endnote (1). The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends.
The following are reconciliations of financial measures of the Company’s segments to the consolidated totals:
| In millions | Health Care Benefits | Health Services (a) | Pharmacy & Consumer Wellness | Corporate/ Other | Intersegment Eliminations (b) | Consolidated Totals | |||||||||||||||||||||||||||||
| Three Months Ended | |||||||||||||||||||||||||||||||||||
| December 31, 2025 | |||||||||||||||||||||||||||||||||||
| Total revenues | $ | 36,293 | $ | 51,244 | $ | 37,660 | $ | 122 | $ | (19,626) | $ | 105,693 | |||||||||||||||||||||||
Adjusted operating income (loss) (1) | (676) | 1,923 | 1,911 | (561) | — | 2,597 | |||||||||||||||||||||||||||||
| December 31, 2024 | |||||||||||||||||||||||||||||||||||
| Total revenues | $ | 32,958 | $ | 47,020 | $ | 33,514 | $ | 83 | $ | (15,865) | $ | 97,710 | |||||||||||||||||||||||
Adjusted operating income (loss) (1) | (439) | 1,761 | 1,758 | (352) | — | 2,728 | |||||||||||||||||||||||||||||
| Year Ended | |||||||||||||||||||||||||||||||||||
| December 31, 2025 | |||||||||||||||||||||||||||||||||||
| Total revenues | $ | 143,354 | $ | 190,425 | $ | 139,367 | $ | 484 | $ | (71,563) | $ | 402,067 | |||||||||||||||||||||||
Adjusted operating income (loss) (1) | 2,939 | 7,151 | 6,040 | (1,687) | — | 14,443 | |||||||||||||||||||||||||||||
| December 31, 2024 | |||||||||||||||||||||||||||||||||||
| Total revenues | $ | 130,665 | $ | 173,605 | $ | 124,500 | $ | 451 | $ | (56,412) | $ | 372,809 | |||||||||||||||||||||||
Adjusted operating income (loss) (1) | 307 | 7,243 | 5,774 | (1,348) | — | 11,976 | |||||||||||||||||||||||||||||
_____________________________________________
(a)Total revenues of the Health Services segment include approximately $2.1 billion and $2.5 billion of retail co-payments for the three months ended December 31, 2025 and 2024, respectively, and $10.9 billion and $11.4 billion of retail co-payments for the years ended December 31, 2025 and 2024, respectively.
(b)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment.
17
Supplemental Information
(Unaudited)
Health Care Benefits segment
The following table summarizes the Health Care Benefits segment’s performance for the respective periods:
| Change | |||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | Three Months Ended December 31, 2025 vs 2024 | Year Ended December 31, 2025 vs 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| In millions, except percentages and basis points (“bps”) | 2025 | 2024 | 2025 | 2024 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 34,018 | $ | 30,902 | $ | 134,749 | $ | 122,849 | $ | 3,116 | 10.1 | % | $ | 11,900 | 9.7 | % | |||||||||||||||||||||||||||||||
| Services | 1,800 | 1,659 | 6,823 | 6,343 | 141 | 8.5 | % | 480 | 7.6 | % | |||||||||||||||||||||||||||||||||||||
| Net investment income | 475 | 397 | 1,782 | 1,473 | 78 | 19.6 | % | 309 | 21.0 | % | |||||||||||||||||||||||||||||||||||||
| Total revenues | 36,293 | 32,958 | 143,354 | 130,665 | 3,335 | 10.1 | % | 12,689 | 9.7 | % | |||||||||||||||||||||||||||||||||||||
| Health care costs | 32,253 | 29,300 | 122,949 | 113,659 | 2,953 | 10.1 | % | 9,290 | 8.2 | % | |||||||||||||||||||||||||||||||||||||
MBR (Health care costs as a % of premium revenues) (3) | 94.8 | % | 94.8 | % | 91.2 | % | 92.5 | % | — | bps | (130) | bps | |||||||||||||||||||||||||||||||||||
| Operating expenses | $ | 4,976 | $ | 4,415 | $ | 18,612 | $ | 17,990 | $ | 561 | 12.7 | % | $ | 622 | 3.5 | % | |||||||||||||||||||||||||||||||
| Operating expenses as a % of total revenues | 13.7 | % | 13.4 | % | 13.0 | % | 13.8 | % | |||||||||||||||||||||||||||||||||||||||
Operating income (loss) | $ | (936) | $ | (757) | $ | 1,793 | $ | (984) | $ | (179) | (23.6) | % | $ | 2,777 | 282.2 | % | |||||||||||||||||||||||||||||||
Operating income (loss) as a % of total revenues | (2.6) | % | (2.3) | % | 1.3 | % | (0.8) | % | |||||||||||||||||||||||||||||||||||||||
Adjusted operating income (loss) (1) | $ | (676) | $ | (439) | $ | 2,939 | $ | 307 | $ | (237) | (54.0) | % | $ | 2,632 | 857.3 | % | |||||||||||||||||||||||||||||||
Adjusted operating income (loss) as a % of total revenues | (1.9) | % | (1.3) | % | 2.1 | % | 0.2 | % | |||||||||||||||||||||||||||||||||||||||
| Premium revenues (by business): | |||||||||||||||||||||||||||||||||||||||||||||||
| Government | $ | 26,562 | $ | 22,164 | $ | 103,362 | $ | 88,433 | $ | 4,398 | 19.8 | % | $ | 14,929 | 16.9 | % | |||||||||||||||||||||||||||||||
| Commercial | 7,456 | 8,738 | 31,387 | 34,416 | (1,282) | (14.7) | % | (3,029) | (8.8) | % | |||||||||||||||||||||||||||||||||||||
The following table summarizes the Health Care Benefits segment’s medical membership for the respective periods:
| December 31, 2025 | September 30, 2025 | December 31, 2024 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| In thousands | Insured | ASC | Total | Insured | ASC | Total | Insured | ASC | Total | ||||||||||||||||||||||||||||||||||||||||||||
Medical membership: (4) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Commercial | 3,447 | 15,350 | 18,797 | 3,536 | 15,314 | 18,850 | 4,691 | 14,160 | 18,851 | ||||||||||||||||||||||||||||||||||||||||||||
| Medicare Advantage | 4,267 | — | 4,267 | 4,266 | — | 4,266 | 4,447 | — | 4,447 | ||||||||||||||||||||||||||||||||||||||||||||
| Medicare Supplement | 1,202 | — | 1,202 | 1,221 | — | 1,221 | 1,282 | — | 1,282 | ||||||||||||||||||||||||||||||||||||||||||||
| Medicaid | 1,952 | 373 | 2,325 | 1,978 | 388 | 2,366 | 2,094 | 421 | 2,515 | ||||||||||||||||||||||||||||||||||||||||||||
| Total medical membership | 10,868 | 15,723 | 26,591 | 11,001 | 15,702 | 26,703 | 12,514 | 14,581 | 27,095 | ||||||||||||||||||||||||||||||||||||||||||||
| Supplemental membership information: | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medicare Prescription Drug Plan (stand-alone) | 4,041 | 4,056 | 4,882 | ||||||||||||||||||||||||||||||||||||||||||||||||||
The following table summarizes the Health Care Benefits segment’s days claims payable for the respective periods:
| December 31, 2025 | September 30, 2025 | June 30, 2025 | March 31, 2025 | December 31, 2024 | |||||||||||||||||||||||||
Days Claims Payable (7) | 38.9 | 42.5 | 40.9 | 43.2 | 44.0 | ||||||||||||||||||||||||
18
Supplemental Information
(Unaudited)
Health Services segment
The following table summarizes the Health Services segment’s performance for the respective periods:
| Change | |||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | Three Months Ended December 31, 2025 vs 2024 | Year Ended December 31, 2025 vs 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| In millions, except percentages | 2025 | 2024 | 2025 | 2024 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
| Products | $ | 48,802 | $ | 44,019 | $ | 180,927 | $ | 162,436 | $ | 4,783 | 10.9 | % | $ | 18,491 | 11.4 | % | |||||||||||||||||||||||||||||||
| Services | 2,432 | 2,713 | 9,478 | 10,884 | (281) | (10.4) | % | (1,406) | (12.9) | % | |||||||||||||||||||||||||||||||||||||
| Net investment income | 10 | 288 | 20 | 285 | (278) | (96.5) | % | (265) | (93.0) | % | |||||||||||||||||||||||||||||||||||||
| Total revenues | 51,244 | 47,020 | 190,425 | 173,605 | 4,224 | 9.0 | % | 16,820 | 9.7 | % | |||||||||||||||||||||||||||||||||||||
| Cost of products sold | 47,209 | 43,358 | 175,634 | 160,036 | 3,851 | 8.9 | % | 15,598 | 9.7 | % | |||||||||||||||||||||||||||||||||||||
| Health care costs | 1,395 | 979 | 4,834 | 3,407 | 416 | 42.5 | % | 1,427 | 41.9 | % | |||||||||||||||||||||||||||||||||||||
Gross profit (8) | 2,640 | 2,683 | 9,957 | 10,162 | (43) | (1.6) | % | (205) | (2.0) | % | |||||||||||||||||||||||||||||||||||||
Gross margin (Gross profit as a % of total revenues) (8) | 5.2 | % | 5.7 | % | 5.2 | % | 5.9 | % | |||||||||||||||||||||||||||||||||||||||
| Operating expenses | $ | 850 | $ | 780 | $ | 4,012 | $ | 3,225 | $ | 70 | 9.0 | % | $ | 787 | 24.4 | % | |||||||||||||||||||||||||||||||
| Operating expenses as a % of total revenues | 1.7 | % | 1.7 | % | 2.1 | % | 1.9 | % | |||||||||||||||||||||||||||||||||||||||
Goodwill impairment | $ | — | $ | — | $ | 5,725 | $ | — | $ | — | — | % | $ | 5,725 | 100.0 | % | |||||||||||||||||||||||||||||||
| Operating income | 1,790 | 1,903 | 220 | 6,937 | (113) | (5.9) | % | (6,717) | (96.8) | % | |||||||||||||||||||||||||||||||||||||
| Operating income as a % of total revenues | 3.5 | % | 4.0 | % | 0.1 | % | 4.0 | % | |||||||||||||||||||||||||||||||||||||||
Adjusted operating income (1) | $ | 1,923 | $ | 1,761 | $ | 7,151 | $ | 7,243 | $ | 162 | 9.2 | % | $ | (92) | (1.3) | % | |||||||||||||||||||||||||||||||
| Adjusted operating income as a % of total revenues | 3.8 | % | 3.7 | % | 3.8 | % | 4.2 | % | |||||||||||||||||||||||||||||||||||||||
| Revenues (by distribution channel): | |||||||||||||||||||||||||||||||||||||||||||||||
Pharmacy network (9) | $ | 27,588 | $ | 25,202 | $ | 101,775 | $ | 91,650 | $ | 2,386 | 9.5 | % | $ | 10,125 | 11.0 | % | |||||||||||||||||||||||||||||||
Mail & specialty (10) | 21,263 | 18,750 | 79,334 | 70,877 | 2,513 | 13.4 | % | 8,457 | 11.9 | % | |||||||||||||||||||||||||||||||||||||
| Other | 2,383 | 2,780 | 9,296 | 10,793 | (397) | (14.3) | % | (1,497) | (13.9) | % | |||||||||||||||||||||||||||||||||||||
| Net investment income | 10 | 288 | 20 | 285 | (278) | (96.5) | % | (265) | (93.0) | % | |||||||||||||||||||||||||||||||||||||
Pharmacy claims processed (5) (6) | 491.9 | 499.4 | 1,900.7 | 1,917.6 | (7.5) | (1.5) | % | (16.9) | (0.9) | % | |||||||||||||||||||||||||||||||||||||
19
Supplemental Information
(Unaudited)
Pharmacy & Consumer Wellness segment
The following table summarizes the Pharmacy & Consumer Wellness segment’s performance for the respective periods:
| Change | |||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | Three Months Ended December 31, 2025 vs 2024 | Year Ended December 31, 2025 vs 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| In millions, except percentages | 2025 | 2024 | 2025 | 2024 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
| Products | $ | 36,845 | $ | 32,833 | $ | 136,575 | $ | 122,028 | $ | 4,012 | 12.2 | % | $ | 14,547 | 11.9 | % | |||||||||||||||||||||||||||||||
| Services | 815 | 681 | 2,792 | 2,472 | 134 | 19.7 | % | 320 | 12.9 | % | |||||||||||||||||||||||||||||||||||||
| Total revenues | 37,660 | 33,514 | 139,367 | 124,500 | 4,146 | 12.4 | % | 14,867 | 11.9 | % | |||||||||||||||||||||||||||||||||||||
| Cost of products sold | 30,578 | 26,710 | 113,583 | 99,337 | 3,868 | 14.5 | % | 14,246 | 14.3 | % | |||||||||||||||||||||||||||||||||||||
Gross profit (8) | 7,082 | 6,804 | 25,784 | 25,163 | 278 | 4.1 | % | 621 | 2.5 | % | |||||||||||||||||||||||||||||||||||||
Gross margin (Gross profit as a % of total revenues) (8) | 18.8 | % | 20.3 | % | 18.5 | % | 20.2 | % | |||||||||||||||||||||||||||||||||||||||
| Operating expenses | $ | 5,236 | $ | 5,110 | $ | 20,924 | $ | 19,646 | $ | 126 | 2.5 | % | $ | 1,278 | 6.5 | % | |||||||||||||||||||||||||||||||
| Operating expenses as a % of total revenues | 13.9 | % | 15.2 | % | 15.0 | % | 15.8 | % | |||||||||||||||||||||||||||||||||||||||
Restructuring charges | $ | — | $ | — | $ | — | $ | 747 | $ | — | — | % | $ | (747) | (100.0) | % | |||||||||||||||||||||||||||||||
| Operating income | 1,846 | 1,694 | 4,860 | 4,770 | 152 | 9.0 | % | 90 | 1.9 | % | |||||||||||||||||||||||||||||||||||||
| Operating income as a % of total revenues | 4.9 | % | 5.1 | % | 3.5 | % | 3.8 | % | |||||||||||||||||||||||||||||||||||||||
Adjusted operating income (1) | $ | 1,911 | $ | 1,758 | $ | 6,040 | $ | 5,774 | $ | 153 | 8.7 | % | $ | 266 | 4.6 | % | |||||||||||||||||||||||||||||||
| Adjusted operating income as a % of total revenues | 5.1 | % | 5.2 | % | 4.3 | % | 4.6 | % | |||||||||||||||||||||||||||||||||||||||
| Revenues (by major goods/service lines): | |||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacy | $ | 31,375 | $ | 27,224 | $ | 115,510 | $ | 100,687 | $ | 4,151 | 15.2 | % | $ | 14,823 | 14.7 | % | |||||||||||||||||||||||||||||||
| Front Store | 5,656 | 5,675 | 21,459 | 21,522 | (19) | (0.3) | % | (63) | (0.3) | % | |||||||||||||||||||||||||||||||||||||
| Other | 629 | 615 | 2,398 | 2,291 | 14 | 2.3 | % | 107 | 4.7 | % | |||||||||||||||||||||||||||||||||||||
Prescriptions filled (5) (6) | 473.8 | 445.9 | 1,808.8 | 1,715.5 | 27.9 | 6.3 | % | 93.3 | 5.4 | % | |||||||||||||||||||||||||||||||||||||
Same store sales increase (decrease): (11) | |||||||||||||||||||||||||||||||||||||||||||||||
| Total | 16.0 | % | 10.2 | % | 15.0 | % | 9.4 | % | |||||||||||||||||||||||||||||||||||||||
| Pharmacy | 19.3 | % | 13.0 | % | 18.0 | % | 12.3 | % | |||||||||||||||||||||||||||||||||||||||
| Front Store | 0.5 | % | (1.2) | % | 1.2 | % | (2.1) | % | |||||||||||||||||||||||||||||||||||||||
Prescription volume (6) | 9.7 | % | 5.9 | % | 8.0 | % | 6.8 | % | |||||||||||||||||||||||||||||||||||||||
20
Supplemental Information
(Unaudited)
Corporate/Other segment
The following table summarizes the Corporate/Other segment’s performance for the respective periods:
| Change | |||||||||||||||||||||||||||||||||||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | Three Months Ended December 31, 2025 vs 2024 | Year Ended December 31, 2025 vs 2024 | ||||||||||||||||||||||||||||||||||||||||||||
| In millions, except percentages | 2025 | 2024 | 2025 | 2024 | $ | % | $ | % | |||||||||||||||||||||||||||||||||||||||
| Revenues: | |||||||||||||||||||||||||||||||||||||||||||||||
| Premiums | $ | 11 | $ | 11 | $ | 45 | $ | 47 | $ | — | — | % | $ | (2) | (4.3) | % | |||||||||||||||||||||||||||||||
| Services | 2 | 2 | 8 | 9 | — | — | % | (1) | (11.1) | % | |||||||||||||||||||||||||||||||||||||
| Net investment income | 109 | 70 | 431 | 395 | 39 | 55.7 | % | 36 | 9.1 | % | |||||||||||||||||||||||||||||||||||||
| Total revenues | 122 | 83 | 484 | 451 | 39 | 47.0 | % | 33 | 7.3 | % | |||||||||||||||||||||||||||||||||||||
| Health care costs | 44 | 45 | 177 | 187 | (1) | (2.2) | % | (10) | (5.3) | % | |||||||||||||||||||||||||||||||||||||
| Operating expenses | 666 | 500 | 2,520 | 2,039 | 166 | 33.2 | % | 481 | 23.6 | % | |||||||||||||||||||||||||||||||||||||
| Restructuring charges | — | 10 | — | 432 | (10) | (100.0) | % | (432) | (100.0) | % | |||||||||||||||||||||||||||||||||||||
| Operating loss | (588) | (472) | (2,213) | (2,207) | (116) | (24.6) | % | (6) | (0.3) | % | |||||||||||||||||||||||||||||||||||||
Adjusted operating loss (1) | (561) | (352) | (1,687) | (1,348) | (209) | (59.4) | % | (339) | (25.1) | % | |||||||||||||||||||||||||||||||||||||
21
Supplemental Information
(Unaudited)
The following table shows the components of the change in the consolidated health care costs payable during the years ended December 31, 2025 and 2024:
| Year Ended December 31, | |||||||||||
| In millions | 2025 | 2024 | |||||||||
Health care costs payable, beginning of the period | $ | 15,064 | $ | 12,049 | |||||||
| Less: Reinsurance recoverables | 81 | 5 | |||||||||
Less: Impact of discount rate on long-duration insurance reserves (a) | (1) | (23) | |||||||||
Health care costs payable, beginning of the period, net | 14,984 | 12,067 | |||||||||
| Add: Components of incurred health care costs | |||||||||||
| Current year | 127,256 | 115,774 | |||||||||
Prior years (b) | (1,982) | (947) | |||||||||
Total incurred health care costs (c) | 125,274 | 114,827 | |||||||||
| Less: Claims paid | |||||||||||
| Current year | 113,023 | 101,583 | |||||||||
| Prior years | 11,906 | 10,327 | |||||||||
| Total claims paid | 124,929 | 111,910 | |||||||||
Health care costs payable, end of the period, net | 15,329 | 14,984 | |||||||||
| Add: Reinsurance recoverables | 90 | 81 | |||||||||
Add: Impact of discount rate on long-duration insurance reserves (a) | (20) | (1) | |||||||||
Health care costs payable, end of the period | $ | 15,399 | $ | 15,064 | |||||||
_____________________________________________
(a)Reflects the difference between the current discount rate and the locked-in discount rate on long-duration insurance reserves which is recorded within accumulated other comprehensive income (loss) on the condensed consolidated balance sheets.
(b)Negative amounts reported for incurred health care costs related to prior years result from claims being settled for amounts less than originally estimated.
(c)Total incurred health care costs for the years ended December 31, 2025 and 2024 in the table above exclude $87 million and $107 million, respectively, of health care costs recorded in the Health Care Benefits segment that are included in other insurance liabilities on the condensed consolidated balance sheets and $177 million and $187 million, respectively, of health care costs recorded in the Corporate/Other segment that are included in other insurance liabilities on the condensed consolidated balance sheets.
22
Adjusted Earnings Per Share Guidance
(Unaudited)
The following reconciliations of projected net income attributable to CVS Health to projected adjusted income attributable to CVS Health and calculations of projected GAAP diluted EPS and projected Adjusted EPS contain forward-looking information. All forward-looking information involves risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking information for a number of reasons as described in our SEC filings, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K and our most recently filed Quarterly Report on Form 10-Q. See “Non-GAAP Financial Information” earlier in this press release and endnote (2) later in this press release for more information on how we calculate Adjusted EPS.
| Year Ending December 31, 2026 | |||||||||||||||||||||||
Low | High | ||||||||||||||||||||||
| In millions, except per share amounts | Total Company | Per Common Share | Total Company | Per Common Share | |||||||||||||||||||
| Net income attributable to CVS Health (GAAP measure) | $ | 7,638 | $ | 5.94 | $ | 7,892 | $ | 6.14 | |||||||||||||||
| Non-GAAP adjustments: | |||||||||||||||||||||||
| Amortization of intangible assets | 1,730 | 1.35 | 1,730 | 1.35 | |||||||||||||||||||
| Acquisition-related integration costs | 80 | 0.06 | 80 | 0.06 | |||||||||||||||||||
| Tax impact of non-GAAP adjustments | (450) | (0.35) | (450) | (0.35) | |||||||||||||||||||
Adjusted income attributable to CVS Health (2) | $ | 8,998 | $ | 7.00 | $ | 9,252 | $ | 7.20 | |||||||||||||||
| Weighted average diluted shares outstanding | 1,285 | 1,285 | |||||||||||||||||||||
23
Endnotes
(1) The Company defines adjusted operating income as operating income (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related integration costs, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, office real estate optimization charges, certain legacy litigation charges, losses on Accountable Care assets and restructuring charges. The CODM uses adjusted operating income as its principal measure of segment performance as it enhances the CODM’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. The consolidated measure is not determined in accordance with GAAP and should not be considered a substitute for, or superior to, the most directly comparable GAAP measure, consolidated operating income. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from consolidated operating income in determining consolidated adjusted operating income.
(2) GAAP diluted earnings per share and Adjusted EPS, respectively, are calculated by dividing net income attributable to CVS Health and adjusted income attributable to CVS Health by the Company’s weighted average diluted shares outstanding. The Company defines adjusted income attributable to CVS Health as net income attributable to CVS Health (GAAP measure) excluding the impact of amortization of intangible assets, net realized capital gains or losses and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance, such as acquisition-related integration costs, goodwill impairment charges, Health Care Delivery clinic closure charges, opioid litigation charges, office real estate optimization charges, certain legacy litigation charges, losses on Accountable Care assets, restructuring charges, gains on early extinguishment of debt, the gain on deconsolidation of subsidiary, the tax benefit from a worthless stock deduction, as well as the corresponding income tax benefit or expense related to the items excluded from adjusted income attributable to CVS Health. See “Non-GAAP Financial Information” earlier in this press release for additional information regarding the items excluded from net income attributable to CVS Health in determining adjusted income attributable to CVS Health.
(3) Medical benefit ratio is calculated by dividing the Health Care Benefits segment’s health care costs by premium revenues and represents the percentage of premium revenues spent on medical benefits for the segment’s insured members. Management uses MBR to assess the underlying business performance and underwriting of its insurance products, understand variances between actual results and expected results and identify trends in period-over-period results. MBR provides management and investors with information useful in assessing the operating results of the Health Care Benefits segment’s insured products.
(4) Medical membership represents the number of members covered by the Health Care Benefits segment’s insured and ASC medical products and related services at a specified point in time. Management uses this metric to understand variances between actual medical membership and expected amounts as well as trends in period-over-period results. This metric provides management and investors with information useful in understanding the impact of medical membership on the Health Care Benefits segment’s total revenues and operating results.
(5) Pharmacy claims processed represents the number of prescription claims processed through the Company’s pharmacy benefits manager and dispensed by either its retail network pharmacies or the Company’s mail and specialty pharmacies. Prescriptions filled represents the number of prescriptions dispensed through the Pharmacy & Consumer Wellness segment’s retail pharmacies and infusion services operations, as well as through the Omnicare long-term care pharmacies prior to their deconsolidation in September 2025. Management uses these metrics to understand variances between actual claims processed and prescriptions dispensed, respectively, and expected amounts as well as trends in period-over-period results. These metrics provide management and investors with information useful in understanding the impact of pharmacy claim volume and prescription volume, respectively, on segment total revenues and operating results.
(6) Includes an adjustment to convert 90-day prescriptions to the equivalent of three 30-day prescriptions. This adjustment reflects the fact that these prescriptions include approximately three times the amount of product days supplied compared to a normal prescription.
24
(7) Days claims payable is calculated by dividing the Health Care Benefits segment’s health care costs payable at the end of each quarter by its average health care costs per day during such quarter. Management and investors use this metric as an indicator of the adequacy of the Health Care Benefits segment’s health care costs payable liability at the end of each quarter and as an indicator of changes in such adequacy over time.
(8) Gross profit is calculated as the segment’s total revenues less its cost of products sold, and, for the Health Services segment, health care costs. Gross margin is calculated by dividing the segment’s gross profit by its total revenues and represents the percentage of total revenues that remains after incurring direct costs associated with the segment’s products sold and services provided. Gross margin provides investors with information that may be useful in assessing the operating results of the Company’s Health Services and Pharmacy & Consumer Wellness segments.
(9) Health Services pharmacy network revenues relate to claims filled at retail and specialty retail pharmacies, including pharmacies owned by the Company, as well as activity associated with Maintenance Choice®, which permits eligible client plan members to fill their maintenance prescriptions through mail order delivery or at a CVS pharmacy retail store for the same price as mail order.
(10) Health Services mail and specialty revenues relate to specialty mail claims inclusive of Specialty Connect® claims picked up at a retail pharmacy, as well as mail order and specialty claims fulfilled by the Pharmacy & Consumer Wellness segment.
(11) Same store sales and prescription volume represent the change in revenues and prescriptions filled in the Company’s retail pharmacy stores that have been operating for greater than one year and digital sales initiated online or through mobile applications and fulfilled through the Company’s distribution centers, expressed as a percentage that indicates the increase or decrease relative to the comparable prior period. Same store metrics exclude revenues and prescriptions from infusion services operations and long-term care pharmacies. Management uses these metrics to evaluate the performance of existing stores on a comparable basis and to inform future decisions regarding existing stores and new locations. Same-store metrics provide management and investors with information useful in understanding the portion of current revenues and prescriptions resulting from organic growth in existing locations versus the portion resulting from opening new stores.
25